Size | Price | Stock | Qty |
---|---|---|---|
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: = 100%
JNJ-31020028 (JNJ31020028) is a potent, high-affinitiy, selective and brain penetrant small molecule antagonist of the neuropeptide Y(2) receptor with pIC50=8.07 (human); pIC50=8.22 (rat); it is >100-fold selective versus human Y1/Y4/Y5 receptors. JNJ-31020028 was >100-fold selective against human Y(1), Y(4), and Y(5) receptors and bound with high affinity (pIC(50) = 8.07 +/- 0.05, human, and pIC(50) = 8.22 +/- 0.06, rat). Functional assays showed that JNJ-31020028 is an antagonist (pK(B) = 8.04 +/- 0.13). After being administered subcutaneously to rats, JNJ-31020028 occupied 90% of the binding sites for the Y(2) receptor at a dose of 10 mg/kg. In line with the colocalization of norepinephrine and neuropeptide Y, JNJ-31020028 enhanced norepinephrine release in the hypothalamus. It was discovered that JNJ-31020028 was ineffective in a number of anxiety models, but that it prevented stress-induced increases in plasma corticosterone without changing basal levels and restored basal food intake in stressed animals.
Targets |
rat Y2 receptor ( pIC50 = 8.22 ); human Y2 receptor ( pIC50 = 8.07 )
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Enzyme Assay |
In functional assays, JNJ-31020028 was shown to be an antagonist (pK(B) = 8.04 +/- 0.13).
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C34H36FN5O2
|
---|---|
Molecular Weight |
565.68
|
Exact Mass |
565.29
|
Elemental Analysis |
C, 72.19; H, 6.41; F, 3.36; N, 12.38; O, 5.66
|
CAS # |
1094873-14-9
|
Related CAS # |
(R)-JNJ-31020028; 1094873-17-2; 1094873-16-1 (S-isomer)
|
Appearance |
White to off-white solid powder
|
SMILES |
CCN(CC)C(=O)C(C1=CC=CC=C1)N2CCN(CC2)C3=C(C=C(C=C3)NC(=O)C4=CC=CC=C4C5=CN=CC=C5)F
|
InChi Key |
OVUNRYUVDVWTTE-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C34H36FN5O2/c1-3-38(4-2)34(42)32(25-11-6-5-7-12-25)40-21-19-39(20-22-40)31-17-16-27(23-30(31)35)37-33(41)29-15-9-8-14-28(29)26-13-10-18-36-24-26/h5-18,23-24,32H,3-4,19-22H2,1-2H3,(H,37,41)
|
Chemical Name |
N-[4-[4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl]-3-fluorophenyl]-2-pyridin-3-ylbenzamide
|
Synonyms |
JNJ 31020028; JNJ31020028; JNJ-31020028
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7678 mL | 8.8389 mL | 17.6778 mL | |
5 mM | 0.3536 mL | 1.7678 mL | 3.5356 mL | |
10 mM | 0.1768 mL | 0.8839 mL | 1.7678 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
(A and C) Digitized computer images of distribution of125I-PYY (A) andN-11C-methyl-JNJ-31020028 (C) binding sites in 20-μm sagittal cryosections of pig brain. Anterior part of brain has been removed so that sections could fit on double-sized microscope slides. (B and D) Inhibition plots of125I-PYY (B) orN-11C-methyl-JNJ-31020028 (D) binding in presence of JNJ-31020028.J Nucl Med.2014 Apr;55(4):635-9. th> |
---|
Parametric images ofN-11C-methyl-JNJ-31020028 BPNDin living pig brain. Image is mean of 4 separate determinations, resampled into MR imaging–based common stereotactic space for pig brain and shown superimposed on MR imaging atlas. Time course of radioactivity concentration studied by PET in living pig brain after intravenous injection ofN-11C-methyl-JNJ-31020028.J Nucl Med.2014 Apr;55(4):635-9. td> |
Metabolism ofN-11C-methyl-JNJ-31020028 measured in blood plasma of pigs after intravenous injection. Symbols are as follows:N-[11C]methyl-JNJ-31020028 (●), first-eluting metabolite (○), second-eluting metabolite (□). Whole-body distribution ofN-11C-methyl-JNJ-31020028 in pig.J Nucl Med.2014 Apr;55(4):635-9. td> |